ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET.

The webcasted presentation will be made available on the Molecular Partners website.

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs

For further details, please contact:  Seth Lewis  seth.lewis@molecularpartners.com  Tel: +1 781 420 2361  Shai Biran, Ph.D.  shai.biran@molecularpartners.com  Tel: +1 978 254 6286  Thomas Schneckenburger, European IR & Media  thomas.schneckenburger@molecularpartners.com  Tel: +41 79 407 9952